XML 109 R65.htm IDEA: XBRL DOCUMENT

Financial assets and liabilities measured at fair value (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Measurement [Abstract]

Summary of Assets and Liabilities Measured at Fair Value

The table below shows the balance sheet amounts of assets and liabilities measured at fair value.


						2022									2021									2020
						Level in the fair value hierarchy									Level in the fair value hierarchy									Level in the fair value hierarchy
(€ million)			Note			Level 1			Level 2			Level 3			Level 1			Level 2			Level 3			Level 1			Level 2			Level 3
Financial assets measured at fair value
Quoted equity investments			D.7.1.			387			—			—			396			—			—			439			—			—
Unquoted equity investments			D.7.1.			—			—			549			—			—			427			—			—			149
Quoted debt securities			D.7.2.			329			—			—			447			—			—			426			—			—
Unquoted debt securities not meeting the definition of equity instruments			D.7.3.			—			—			115			—			—			78			—			—			63
Contingent consideration relating to divestments			D.7.3.			—			—			303			—			—			378			—			—			483

Financial assets held to meet obligations under deferred compensation plans			D.7.3. and D.11.			512			—			—			549			—			—			454			—			—
Non-current derivatives			D.7.			—			—			—			—			3			—			—			24			—
Current derivatives			D.11.			—			206			—			—			295			—			—			58			—
Mutual fund investments			D.13.			9,537			—			—			5,057			—			—			8,703			—			—
Total financial assets measured at fair value						10,765			206			967			6,449			298			883			10,022			82			695
Financial liabilities measured at fair value

Bayer contingent purchase consideration arising from the acquisition of Genzyme			D.18.			—			—			26			—			—			59			—			—			104
MSD contingent consideration (European vaccines business)			D.18.			—			—			204			—			—			269			—			—			312
Shire contingent consideration arising from the acquisition of Translate Bio			D.18.			—			—			380			—			—			354			—			—			—
Contingent consideration arising from acquisition of Amunix			D.18.			—			—			165			—			—			—			—			—			—
Other contingent consideration arising from business combinations and acquisitions			D.18.			—			—			4			—			—			32			—			—			189

Non-current derivatives			D.19.			—			232			—			—			6			—			—			92			—
Current derivatives			D.19.5			—			94			—			—			79			—			—			205			—
Total financial liabilities measured at fair value						—			326			779			—			85			714			—			297			605